These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 38957949)

  • 1. Chemogenetic Tools and their Use in Studies of Neuropsychiatric Disorders.
    Neřoldová M; Stuchlík A
    Physiol Res; 2024 Aug; 73(S1):S449-S470. PubMed ID: 38957949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of clozapine-N-oxide and compound 21 on sleep in laboratory mice.
    Traut J; Mengual JP; Meijer EJ; McKillop LE; Alfonsa H; Hoerder-Suabedissen A; Song SH; Fehér KD; Riemann D; Molnar Z; Akerman CJ; Vyazovskiy VV; Krone LB
    Elife; 2023 Mar; 12():. PubMed ID: 36892930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Behavioral Manipulation via Orally Delivered Chemogenetic Actuator in Macaques.
    Oyama K; Hori Y; Nagai Y; Miyakawa N; Mimura K; Hirabayashi T; Inoue KI; Takada M; Higuchi M; Minamimoto T
    J Neurosci; 2022 Mar; 42(12):2552-2561. PubMed ID: 35110390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A novel ligand for chemogenetic receptors, Deschloroclozapine, enables rapid and selective modulation of neuronal activity and behavior in living animals].
    Nagai Y
    Nihon Yakurigaku Zasshi; 2022; 157(4):233-237. PubMed ID: 35781451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral Effect of Chemogenetic Inhibition Is Directly Related to Receptor Transduction Levels in Rhesus Monkeys.
    Upright NA; Brookshire SW; Schnebelen W; Damatac CG; Hof PR; Browning PGF; Croxson PL; Rudebeck PH; Baxter MG
    J Neurosci; 2018 Sep; 38(37):7969-7975. PubMed ID: 30082415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemogenetics drives paradigm change in the investigation of behavioral circuits and neural mechanisms underlying drug action.
    Ozawa A; Arakawa H
    Behav Brain Res; 2021 May; 406():113234. PubMed ID: 33741409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
    Chen X; Choo H; Huang XP; Yang X; Stone O; Roth BL; Jin J
    ACS Chem Neurosci; 2015 Mar; 6(3):476-84. PubMed ID: 25587888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity.
    Zhan J; Komal R; Keenan WT; Hattar S; Fernandez DC
    J Vis Exp; 2019 Aug; (150):. PubMed ID: 31498301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral Vector Delivery of DREADDs for CNS Therapy.
    Pickering CA; Mazarakis ND
    Curr Gene Ther; 2021; 21(3):191-206. PubMed ID: 33573551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.
    Gomez JL; Bonaventura J; Lesniak W; Mathews WB; Sysa-Shah P; Rodriguez LA; Ellis RJ; Richie CT; Harvey BK; Dannals RF; Pomper MG; Bonci A; Michaelides M
    Science; 2017 Aug; 357(6350):503-507. PubMed ID: 28774929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemogenetic modulation of sensory afferents induces locomotor changes and plasticity after spinal cord injury.
    Eisdorfer JT; Sobotka-Briner H; Schramfield S; Moukarzel G; Chen J; Campion TJ; Smit R; Rauscher BC; Lemay MA; Smith GM; Spence AJ
    Front Mol Neurosci; 2022; 15():872634. PubMed ID: 36090254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of DREADDs to Deconstruct Behavior.
    Whissell PD; Tohyama S; Martin LJ
    Front Genet; 2016; 7():70. PubMed ID: 27242888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does chronic systemic injection of the DREADD agonists clozapine-N-oxide or Compound 21 change behavior relevant to locomotion, exploration, anxiety, and depression in male non-DREADD-expressing mice?
    Tran FH; Spears SL; Ahn KJ; Eisch AJ; Yun S
    Neurosci Lett; 2020 Nov; 739():135432. PubMed ID: 33080350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemogenetic Activation of Excitatory Neurons Alters Hippocampal Neurotransmission in a Dose-Dependent Manner.
    Pati S; Salvi SS; Kallianpur M; Vaidya B; Banerjee A; Maiti S; Clement JP; Vaidya VA
    eNeuro; 2019; 6(6):. PubMed ID: 31645362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral Effects of Acute Systemic Low-Dose Clozapine in Wild-Type Rats: Implications for the Use of DREADDs in Behavioral Neuroscience.
    Ilg AK; Enkel T; Bartsch D; Bähner F
    Front Behav Neurosci; 2018; 12():173. PubMed ID: 30154702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility.
    Urban DJ; Roth BL
    Annu Rev Pharmacol Toxicol; 2015; 55():399-417. PubMed ID: 25292433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Intersectional Approach to Target Neural Circuits With Cell- and Projection-Type Specificity: Validation in the Mesolimbic Dopamine System.
    Kakava-Georgiadou N; Zwartkruis MM; Bullich-Vilarrubias C; Luijendijk MCM; Garner KM; van der Plasse G; Adan RAH
    Front Mol Neurosci; 2019; 12():49. PubMed ID: 30873002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated chemogenetic activation of dopaminergic neurons induces reversible changes in baseline and amphetamine-induced behaviors.
    Chohan MO; Fein H; Mirro S; O'Reilly KC; Veenstra-VanderWeele J
    Psychopharmacology (Berl); 2023 Dec; 240(12):2545-2560. PubMed ID: 37594501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer Drugs.
    Burnett CJ; Krashes MJ
    J Neurosci; 2016 Sep; 36(36):9268-82. PubMed ID: 27605603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodal Imaging for Validation and Optimization of Ion Channel-Based Chemogenetics in Nonhuman Primates.
    Hori Y; Nagai Y; Hori Y; Oyama K; Mimura K; Hirabayashi T; Inoue KI; Fujinaga M; Zhang MR; Takada M; Higuchi M; Minamimoto T
    J Neurosci; 2023 Sep; 43(39):6619-6627. PubMed ID: 37620158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.